The PI3K-AKT-mTOR signaling axis—one of the most frequently deregulated pathways in prostate cancer—contributes to tumor growth and therapy resistance by regulating cell proliferation, survival, and metabolic reprogramming. Here, MTOR is linked to neoplasm.